Former FDA Commissioner Dr. Scott Gottlieb recently penned an op-ed in the Washington Post titled “The CBD craze is getting out of hand. The FDA needs to act.” In the piece, Dr. Gottlieb proposed an expedited process to permit cannabidiol (CBD) to be added to foods and drinks and marketed as a supplement.

Since the passage of the Farm Bill in December of 2018 that legalized hemp and hemp-derived CBD, there has been a spike in interest in CBD products. The FDA, however, must approve products containing CBD (at least those for human consumption that are intended for interstate commerce) because CBD is an active ingredient in an FDA-approved drug. While the FDA has been actively investigating a more-permissive approach to CBD, as Dr. Gottlieb noted, the traditional path for FDA approval is a multiyear process. Dr. Gottlieb expressed concern (as we did here) that the market cannot wait years for approval, and that the FDA is at risk of being rendered irrelevant as consumers clamor for CBD products and the market responds.

Dr. Gottlieb suggested a hybrid approach that, from his perspective, would reasonably open the CBD market, while still allowing the FDA to continue to reasonably evaluate the safety of CBD products. Under this approach, manufacturers would be able to immediately petition the FDA for permission to include CBD in their products, with such petitions providing evidence for the safety of the product. The FDA, in turn, would use its enforcement power liberally but with discretion, focusing (as it largely is now) on those making unsubstantiated health claims regarding CBD products. In other words, the FDA would crack down hard on claims that CBD is a treatment for cancer, while approving (or not cracking down on) manufacturers making reputable products and claims about the effects of CBD.

Dr. Gottlieb’s proposal needs some fleshing out, as it is not clear why any entity would go to the trouble and expense of petitioning for permission from the FDA if it knows the FDA is only going to be cracking down on seriously misleading health claims. A petition process would seem to only work if it is combined with a robust enforcement approach, and there does not appear to be the political willpower or resources for such a crackdown. The import of the op-ed is thus more symbolic than substantive. Dr. Gottlieb is no longer making policy for the FDA, but by publicly pushing for a more-permissive and speedier approach, he is certainly sending a pro-CBD signal to the FDA and CBD manufacturers. We continue to believe that the FDA is going to propose a plan for legalizing CBD for human consumption sooner rather than later.

Former FDA Commissioner Pushes Expedited Authorization for CBD Products


NACB Latest News

Mark Taylor

Our European Editor has published the title.

Cannabis Law & Regulation with UK Publisher. Bloomsbury Professional

Green Entrepreneur

Sponsor – aBizinaBox

Cannabis Law Report Supports
Extinction Rebellion Earth

Sponsor – Cannabis Law Digest

  • The Jazz Club 2 LLC v. Detroit Board of Zoning Appeals

    No. 343872 (Mich. Ct. App. 2020)Where (1) the zoning ordinance prohibits a medical marijuana caregiver center from being located within a drug-free […]

  • Hager v. M&K Construction

    No. A-0102-18T3 (N.J. Super. Ct. App. Div. 2020)An employer is required to reimburse its employee for the employee's use of medical marijuana […]

  • Cloudi Mornings, LLC. v. City of Broken Arrow

    2019 OK 75 (Okla. 2019)Although Oklahoma State Question 788A provided that no local municipality may unduly restrict or change zoning laws to prevent […]

  • Ryan v. Henry II

    18-0660 (Ariz. Ct. App. 2019)Garnishment proceedings seeking to garnish funds of former operators of a marijuana business, against whom judgment was […]

  • Greenwood v. Green Leaf Lab LLC

    No. 3:17-cv-00415-PK, 2017 U.S. Dist. LEXIS 125143 (D. Or. 2017)Despite marijuana’s illegality under federal law, employers in the marijuana […]

Upcoming Events


    January 26 @ 8:00 am - February 29 @ 5:00 pm UTC+0
  2. Texas Hemp Convention

    January 28 @ 8:00 am - January 30 @ 5:00 pm UTC+0

    January 29 @ 8:00 am - January 30 @ 5:00 pm UTC+0
  4. Asian Hemp Summit – KATHMANDU, in beautiful NEPAL!

    January 31 @ 8:00 am - February 1 @ 5:00 pm UTC+0
  5. February 1


Judge Throws Out Cannabis Possession Case as state lab testifies in court it can’t tell difference between legal hemp and illegal marijuana

Colorado Supreme Court Asked To Rule On, "Can A Judge Tell A Coloradan On Probation Not To Consume Medical Marijuana? "

Load More...

Top Marijuana Blog

CFN Media Podcasts

%d bloggers like this: